Search results
Results from the WOW.Com Content Network
ConnectWise ScreenConnect, previously ConnectWise Control, is a self-hosted remote desktop software application. It was originally developed by Elsinore Technologies in 2008 under the name ScreenConnect , and is now owned by ConnectWise Inc.
PAM solutions play a crucial role in reducing security vulnerabilities, adhering to information security standards, and protecting an organization's IT infrastructure.. They establish a comprehensive system for handling privileged accounts, encompassing the gathering, safeguarding, administration, verification, documentation, and examination of privileged acces
Splashtop Inc. is a privately held software company founded in 2006 and headquartered in Silicon Valley.. The company was founded in 2006 under the name DeviceVM Inc. Its first product, named Splashtop OS, was an ‘instant-on’ Linux-based computing platform.
[12] The review said EndPoint Protection had a "no-brainer setup and administration," but it does have a "wart" that support fees are "a bit steep." [12] Forrester said version 12.1 was the most complete endpoint security software product on the market, but the different IT security functions of the software were not well-integrated. [22]
Network Access Protection (NAP) is a Microsoft technology for controlling network access of a computer, based on its health.It was first included in Windows Vista and Windows Server 2008 and backported to Windows XP Service Pack 3.
CrushFTP supports the following protocols: FTP, FTPS, SFTP, HTTP, HTTPS, WebDAV and WebDAV SSL. Additionally, although not a protocol, it has both AJAX/HTML5 and Java applet web interfaces for end users to manage their files from a web browser.
St Andrew's College, also known as StAC, in Christchurch, New Zealand, is a private, co-educational school that enrols from pre-school to secondary Year 13.It was founded in 1917 and it is the only independent, co-educational primary and secondary school in New Zealand's South Island.
AOH1996 is an experimental anticancer medication which acts as a small molecule inhibitor of proliferating cell nuclear antigen (PCNA) and is in Phase I clinical trials at City of Hope as of August 2023 for the treatment of solid tumors.